Intestinal Colonization of Preterm Neonates with Carbapenem Resistant Enterobacteria at Hospital Discharge
Overview
Authors
Affiliations
Our aim was to investigate gut colonization with carbapenem-resistant Enterobacterales (CRE) in the population of preterm neonates at discharge from a tertiary care center in Serbia. The study included 350 randomly selected neonates/infants discharged in the period April 2018-May 2019. CRE colonization was present in 88/350 (25.1%) of patients. producing KPC and OXA-48 carbapenemase were detected in 45 and 42 subjects, respectively, while NDM producing was identified in one patient only. All OXA-48 strains harbored , while both and were present in all but one KPC-producing strain. CRE isolates exhibited a multidrug resistance pattern with uniform fluoroquinolone resistance, universal susceptibility to colistin, and variable susceptibility to aminoglycosides. Administration of carbapenems was common (~50%) and it was strongly associated with colonization, as well as the combinational therapeutic regimens that included meropenem, contrary to ampicillin-sulbactam/colistin therapy and prolonged course of the initial therapy (ampicillin/amikacin ≥ 7 days). Other risk factors for CRE carriage were level of immaturity, admission to neonatal intensive care unit, prolonged hospitalization and invasive procedures. Although the rate of clinically and/or laboratory proven systemic infections was significantly higher among colonized patients, CRE infection was confirmed in one patient only (1.1%) that was colonized with NDM . Clonal relatedness of CRE isolates was high, with seven and eight clusters detected among KPC (N = 30) and OXA-48 (N = 37) producing strains, respectively. The follow up of the 31 KPC-colonized patients after discharge from hospital revealed common decolonization within one month (~68%). In conclusion, our results demonstrated a high rate of CRE colonization that is most likely related to carbapenem consumption and lack of screening as important infection prevention practice.
Yu Z, Li L, Cheng P, Zhang H, Xu S Sci Rep. 2024; 14(1):29486.
PMID: 39604506 PMC: 11603295. DOI: 10.1038/s41598-024-80974-2.
Ma J, Gao K, Li M, Zhou J, Song X, Zhang Y Ann Clin Microbiol Antimicrob. 2024; 23(1):98.
PMID: 39511610 PMC: 11545200. DOI: 10.1186/s12941-024-00757-5.
Beaumont A, Kermorvant-Duchemin E, Breurec S, Huynh B JAMA Netw Open. 2024; 7(11):e2441596.
PMID: 39499519 PMC: 11581591. DOI: 10.1001/jamanetworkopen.2024.41596.
Carbapenem-Resistant in the Western Balkans: Addressing Gaps in European AMR Surveillance Map.
Brkic S, Cirkovic I Antibiotics (Basel). 2024; 13(9).
PMID: 39335068 PMC: 11428970. DOI: 10.3390/antibiotics13090895.
Moussa B, Hmami F, Arhoun B, El Fakir S, Massik A, Belchkar S Cureus. 2024; 15(12):e50095.
PMID: 38186478 PMC: 10770769. DOI: 10.7759/cureus.50095.